The therapeutic perspective of NAD+ precursors in age-related diseases
Biochemical and Biophysical Research Communications · 2024-04 · 702 · 149590
DOI: 10.1016/j.bbrc.2024.149590 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2024-04. Verfasst von Tooba Iqbal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: NAD, Dietary Supplements. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Nicotinamide adenine dinucleotide (NAD+) is the fundamental molecule that performs numerous biological reactions and is crucial for maintaining cellular homeostasis. Studies have found that NAD+ decreases with age in certain tissues, and age-related NAD+ depletion affects physiological functions and contributes to various aging-related diseases. Supplementation of NAD+ precursor significantly elevates NAD+ levels in murine tissues, effectively mitigates metabolic syndrome, enhances cardiovascular health, protects against neurodegeneration, and boosts muscular strength. Despite the versatile therapeutic functions of NAD+ in animal studies, the efficacy of NAD+ precursors in clinical studies have been limited compared with that in the pre-clinical study. Clinical studies have demonstrated that NAD+ precursor treatment efficiently increases NAD+ levels in various tissues, though their clinical proficiency is insufficient to ameliorate the diseases. However, the latest studies regarding NAD+ precursors and their metabolism highlight the significant role of gut microbiota. The studies found that orally administered NAD+ intermediates interact with the gut microbiome. These findings provide compelling evidence for future trials to further explore the involvement of gut microbiota in NAD+ metabolism. Also, the reduced form of NAD+ precursor shows their potential to raise NAD+, though preclinical studies have yet to discover their efficacy. This review sheds light on NAD+ therapeutic efficiency in preclinical and clinical studies and the effect of the gut microbiota on NAD+ metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan.
- Department of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan; Research Center for Pre-Disease Science, University of Toyama, Toyama, Japan. Electronic address: nakagawa@med.…
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Iqbal, T., & Nakagawa, T. (2024). The therapeutic perspective of NAD+ precursors in age-related diseases. Biochemical and Biophysical Research Communications, 702, 149590. https://doi.org/10.1016/j.bbrc.2024.149590
Vancouver
Iqbal T, Nakagawa T. The therapeutic perspective of NAD+ precursors in age-related diseases. Biochemical and Biophysical Research Communications. 2024;702:149590. doi:10.1016/j.bbrc.2024.149590
BibTeX
@article{Iqbal2024,
author = {Iqbal, Tooba and Nakagawa, Takashi},
title = {The therapeutic perspective of NAD+ precursors in age-related diseases},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
volume = {702},
pages = {149590},
doi = {10.1016/j.bbrc.2024.149590}
}
EUVIMED